Geron mit Hammernews!! - Älteste Beiträge zuerst
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 21.03.24 13:47:21 von
neuester Beitrag 21.03.24 13:47:21 von
Beiträge: 3.090
ID: 709.348
ID: 709.348
Aufrufe heute: 0
Gesamt: 213.061
Gesamt: 213.061
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GERN
3,5600
USD
-0,56 %
-0,0200 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
25.04.24 · Business Wire (engl.)  |
18.04.24 · Business Wire (engl.) |
03.04.24 · Business Wire (engl.) |
19.03.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 1,9700 | +15,20 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -13,71 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 1,6052 | -30,21 | |
| 0,5121 | -30,80 |
Feedback
Aktie steigt über 65 %
Hier die Meldung:Erfolg bei Krebsbekämpfung
03/18/2003
Dow Jones News Services
(Copyright © 2003 Dow Jones & Company, Inc.)
MENLO PARK, Calif. (Dow Jones)--Recent research results indicate that Geron Corp.`s (GERN) telomerase cancer vaccine is effective in all cancer patients, even those with tumors that don`t have any known tumor-associated antigens.
In a press release Tuesday, the biopharmaceutical company said telomerase is activated in all human cancer types and is therefore an attractive candidate for use as a universal cancer vaccine.
Geron`s study involved melanoma and colon cancer cell lines that are known to express tumor-associated antigens, as well as another line lacking any known tumor antigen.
The study shows that cells genetically modified with the telomerase gene can be used to generate an immune response against cancer cells, Geron said. This response killed all three tumor cell lines in the study.
Company representatives weren`t immediately available for more information.
A phase I study of telomerase is under way in patients with metastatic prostate cancer.
Geron`s shares traded recently at $2.75, up $1.02, or 58.8%, on Nasdaq volume of 1.3 million shares. Average daily volume is 134,102 shares. The stock hit a 52-week high of $8.80 on April 9 and a 52-week low of $1.41 on March 11.
Hier die Meldung:Erfolg bei Krebsbekämpfung
03/18/2003
Dow Jones News Services
(Copyright © 2003 Dow Jones & Company, Inc.)
MENLO PARK, Calif. (Dow Jones)--Recent research results indicate that Geron Corp.`s (GERN) telomerase cancer vaccine is effective in all cancer patients, even those with tumors that don`t have any known tumor-associated antigens.
In a press release Tuesday, the biopharmaceutical company said telomerase is activated in all human cancer types and is therefore an attractive candidate for use as a universal cancer vaccine.
Geron`s study involved melanoma and colon cancer cell lines that are known to express tumor-associated antigens, as well as another line lacking any known tumor antigen.
The study shows that cells genetically modified with the telomerase gene can be used to generate an immune response against cancer cells, Geron said. This response killed all three tumor cell lines in the study.
Company representatives weren`t immediately available for more information.
A phase I study of telomerase is under way in patients with metastatic prostate cancer.
Geron`s shares traded recently at $2.75, up $1.02, or 58.8%, on Nasdaq volume of 1.3 million shares. Average daily volume is 134,102 shares. The stock hit a 52-week high of $8.80 on April 9 and a 52-week low of $1.41 on March 11.
Hier ein ausführlicher Bericht
MENLO PARK, Calif.--(BUSINESS WIRE)--March 18, 2003--Geron Corporation (Nasdaq:GERN - News) announced today the publication of research results that support the utility of telomerase for widespread applications in cancer immunotherapy.
ADVERTISEMENT
The research, published in the March 2003 issue of Cancer Gene Therapy, shows that different types of cancer cells, including cancer cells without any known tumor-associated antigens, can be killed by telomerase-based immunotherapy. Geron scientists studied melanoma and colon cancer cell lines that are known to express the tumor-associated antigens, MART-1 and CEA-1, respectively, and an osteosarcoma line lacking any known tumor antigen. Telomerase was introduced into human dendritic cells by gene transfer enabling the dendritic cells to generate telomerase specific cytotoxic T-lymphocytes (CTLs) that killed all three tumor cell lines. These findings show that telomerase vaccination can be used in all cancer patients, even those with tumors that do not express any known tumor-associated antigens.
Telomerase is activated in all human cancer types, including breast, lung, colon, prostate, pancreatic and hematologic tumors. Telomerase is therefore an attractive candidate for use as a universal therapeutic cancer vaccine. A Phase 1 study of Geron`s ex-vivo telomerase vaccine is currently underway in patients with metastatic prostate cancer at Duke University Medical Center.
Study Results
In the study, Geron scientists were able to show that dendritic cells (the most potent antigen presenting cells in the body) obtained from the peripheral blood of normal healthy volunteers can be modified in vitro with purified human telomerase DNA or with an adenoviral vector containing human telomerase DNA. The resulting telomerase-modified dendritic cells then present antigenic fragments of the telomerase protein to T-lymphocytes, thereby enabling them to recognize and kill telomerase-positive cancer cells. This study shows that dendritic cells genetically modified with the telomerase gene can be used to generate an immune response against cancer cells, and extends previous work that showed similar results using telomerase RNA (Nature Medicine 2000;6:1011-1017) or telomerase peptides (Proc. Natl. Acad. Sci. USA 2000; 25:4796-4801) as antigens. These results support the potential use of telomerase as a universal cancer vaccine administered directly to cancer patients in order to induce a strong and specific anti-telomerase immune response in which the patients own lymphocytes recognize and kill telomerase-expressing cancer cells.
"The universal expression of telomerase in cancer cells forms the rationale for our ongoing programs in telomerase inhibition (GRN163), telomerase oncolytic viruses (partnered with Genetic Therapy, Inc./ Novartis), and telomerase immunotherapy, currently in Phase 1 clinical trials at Duke," said David B. Karpf, Geron`s executive medical director of oncology. "This study provides additional support for the use of telomerase in cancer vaccine trials, and suggests that telomerase-based immunotherapy may be useful for all cancer patients regardless of the tumor antigen status of their cancer cells."
Physicians or patients who would like more information on the Duke telomerase vaccine trial may contact the clinical trials coordinator at 919/668-3457.
Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron`s product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells, and nuclear transfer.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation`s technology constitute statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for additional capital, regulatory approvals and clearances, and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron`s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2002.
MENLO PARK, Calif.--(BUSINESS WIRE)--March 18, 2003--Geron Corporation (Nasdaq:GERN - News) announced today the publication of research results that support the utility of telomerase for widespread applications in cancer immunotherapy.
ADVERTISEMENT
The research, published in the March 2003 issue of Cancer Gene Therapy, shows that different types of cancer cells, including cancer cells without any known tumor-associated antigens, can be killed by telomerase-based immunotherapy. Geron scientists studied melanoma and colon cancer cell lines that are known to express the tumor-associated antigens, MART-1 and CEA-1, respectively, and an osteosarcoma line lacking any known tumor antigen. Telomerase was introduced into human dendritic cells by gene transfer enabling the dendritic cells to generate telomerase specific cytotoxic T-lymphocytes (CTLs) that killed all three tumor cell lines. These findings show that telomerase vaccination can be used in all cancer patients, even those with tumors that do not express any known tumor-associated antigens.
Telomerase is activated in all human cancer types, including breast, lung, colon, prostate, pancreatic and hematologic tumors. Telomerase is therefore an attractive candidate for use as a universal therapeutic cancer vaccine. A Phase 1 study of Geron`s ex-vivo telomerase vaccine is currently underway in patients with metastatic prostate cancer at Duke University Medical Center.
Study Results
In the study, Geron scientists were able to show that dendritic cells (the most potent antigen presenting cells in the body) obtained from the peripheral blood of normal healthy volunteers can be modified in vitro with purified human telomerase DNA or with an adenoviral vector containing human telomerase DNA. The resulting telomerase-modified dendritic cells then present antigenic fragments of the telomerase protein to T-lymphocytes, thereby enabling them to recognize and kill telomerase-positive cancer cells. This study shows that dendritic cells genetically modified with the telomerase gene can be used to generate an immune response against cancer cells, and extends previous work that showed similar results using telomerase RNA (Nature Medicine 2000;6:1011-1017) or telomerase peptides (Proc. Natl. Acad. Sci. USA 2000; 25:4796-4801) as antigens. These results support the potential use of telomerase as a universal cancer vaccine administered directly to cancer patients in order to induce a strong and specific anti-telomerase immune response in which the patients own lymphocytes recognize and kill telomerase-expressing cancer cells.
"The universal expression of telomerase in cancer cells forms the rationale for our ongoing programs in telomerase inhibition (GRN163), telomerase oncolytic viruses (partnered with Genetic Therapy, Inc./ Novartis), and telomerase immunotherapy, currently in Phase 1 clinical trials at Duke," said David B. Karpf, Geron`s executive medical director of oncology. "This study provides additional support for the use of telomerase in cancer vaccine trials, and suggests that telomerase-based immunotherapy may be useful for all cancer patients regardless of the tumor antigen status of their cancer cells."
Physicians or patients who would like more information on the Duke telomerase vaccine trial may contact the clinical trials coordinator at 919/668-3457.
Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron`s product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells, and nuclear transfer.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation`s technology constitute statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for additional capital, regulatory approvals and clearances, and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron`s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2002.
Übersetzung von # 1 Impfstoff gegen KREBS!!
MENLO-PARK, Calif. (Dow Jones) -- neue Forschungsresultate zeigen an, daß telomerase-Krebsimpfstoff Geron Corp.`s (GERN) bei allen Krebspatienten wirkungsvoll ist, sogar die mit Tumoren, daß don`t alle bekannten Tumor-dazugehörigen Antigene haben. In einem Pressekommuniqué Dienstag, wird die biopharmaceutical gesagte Firma telomerase in allen menschlichen Krebsarten aktiviert und ist folglich ein attraktiver Anwärter für Gebrauch als Universalkrebsimpfstoff. Studie Geron`s bezog melanoma- und Doppelpunktkrebszellenlinien, die bekannt, um Tumor-dazugehörige Antigene auszudrücken, sowie eine andere Linie mit ein, die jedes mögliches bekannte Tumorantigen ermangelt. Die Studie zeigt, daß die Zellen, die genetisch mit dem telomerasegen geändert werden, benutzt werden können, um eine immune Antwort gegen Krebszellen zu erzeugen, gesagtes Geron. Diese Antwort tötete alle drei Tumorzellenlinien in der Studie. Firmarepräsentantenweren`t sofort vorhanden zu mehr Information. Eine Phase, die ich vom telomerase studiere, ist unterwegs bei Patienten mit metastatic Prostatakrebs.
MENLO-PARK, Calif. (Dow Jones) -- neue Forschungsresultate zeigen an, daß telomerase-Krebsimpfstoff Geron Corp.`s (GERN) bei allen Krebspatienten wirkungsvoll ist, sogar die mit Tumoren, daß don`t alle bekannten Tumor-dazugehörigen Antigene haben. In einem Pressekommuniqué Dienstag, wird die biopharmaceutical gesagte Firma telomerase in allen menschlichen Krebsarten aktiviert und ist folglich ein attraktiver Anwärter für Gebrauch als Universalkrebsimpfstoff. Studie Geron`s bezog melanoma- und Doppelpunktkrebszellenlinien, die bekannt, um Tumor-dazugehörige Antigene auszudrücken, sowie eine andere Linie mit ein, die jedes mögliches bekannte Tumorantigen ermangelt. Die Studie zeigt, daß die Zellen, die genetisch mit dem telomerasegen geändert werden, benutzt werden können, um eine immune Antwort gegen Krebszellen zu erzeugen, gesagtes Geron. Diese Antwort tötete alle drei Tumorzellenlinien in der Studie. Firmarepräsentantenweren`t sofort vorhanden zu mehr Information. Eine Phase, die ich vom telomerase studiere, ist unterwegs bei Patienten mit metastatic Prostatakrebs.
Aktueller Kurs 3,15 Dollar +82 % und es wird noch höher gehen Impfstoff gegen Krebs was will man mehr1 Sicherlich es wird Jahre vergehen und klinische Studien dauern lange und kosten Geld und dieses hat die Firma leider nicht in Mengen. Es gibt aber noch andere Möglichkeiten z,b. Kooperationspartner , Beteiligungen von Venture Capitel Firmen oder über die Ausgabe von neuen Aktien was am warscheinlichsten ist.
Aktuell 4,35 Dollar +150 %!!!!!!!!!!!!!!!
Trading Spotlight
4,70 Dollar +175%!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Fällt heute die 6 Dollar Marke?
Für alle die nicht dabei sind ein Trost gibt es
Die Geissel Krebs wird vielleicht bekämpft werden können und das mit einer Impfung .Hat doch auch seinen Charme wie ich meine!!
gruss meislo
Für alle die nicht dabei sind ein Trost gibt es
Die Geissel Krebs wird vielleicht bekämpft werden können und das mit einer Impfung .Hat doch auch seinen Charme wie ich meine!!
gruss meislo
Hi,
was sehen meine entzündeten Augen !! GERON + 175 %
bin dabei !!!!!!
ABER: meine Einstiegskurse (irgendwann 1998 oder 1999 und dann noch mal billig nachgestiegen) sind leider auch ASTRONOMISCH!! hoch.
edgar
was sehen meine entzündeten Augen !! GERON + 175 %
bin dabei !!!!!!
ABER: meine Einstiegskurse (irgendwann 1998 oder 1999 und dann noch mal billig nachgestiegen) sind leider auch ASTRONOMISCH!! hoch.
edgar
Hallo Edgar
Ich gehe davon aus das Du sie schon abgeschrieben hattest
So keimt nun doch wieder die Hoffnung auf und es zeigt sich das Geron von den Toten auferstanden ist. Sicher ist es noch ein weiter und steiniger Weg bis Geron alte Stärke zeigen wird!
gruss meislo
Ich gehe davon aus das Du sie schon abgeschrieben hattest
So keimt nun doch wieder die Hoffnung auf und es zeigt sich das Geron von den Toten auferstanden ist. Sicher ist es noch ein weiter und steiniger Weg bis Geron alte Stärke zeigen wird!
gruss meislo
1:39pm ET
4.58
2.85 (164.73%)
Day`s Range: 2.00 - 5.37
Day`s Volume: 8,268,340
Avg. Volume: 0
4.58
2.85 (164.73%)
Day`s Range: 2.00 - 5.37
Day`s Volume: 8,268,340
Avg. Volume: 0
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,33 | |
| +0,29 | |
| -0,76 | |
| +23,94 | |
| -2,70 | |
| +0,23 | |
| -0,15 | |
| -3,49 | |
| -0,76 | |
| -0,12 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 245 | ||
| 99 | ||
| 83 | ||
| 79 | ||
| 75 | ||
| 52 | ||
| 41 | ||
| 38 | ||
| 36 | ||
| 33 |
